Keyphrases
Retinoblastoma
100%
Bevacizumab
91%
Triamcinolone Acetonide
91%
Open Globe Injury
66%
Injury Model
66%
Transforming Growth Factor-β
50%
Plasminogen Activator inhibitor-1 (PAI-1)
50%
Right Eye
45%
Orbital Cellulitis
44%
Tumor Necrosis Factor-α
41%
Interleukin-10
41%
Visual Acuity
41%
Immunocompromised Patients
41%
Proliferative Vitreoretinopathy
40%
National Income Level
38%
Treatment Outcome
38%
Clinical Presentation
36%
Enucleation
35%
Anti-inflammatory Effect
33%
Eye Health
33%
Keratitis
33%
Scleromalacia Perforans
33%
Ocular Stem Cells
33%
Limbal Stem Cell Niche
33%
Epigallocatechin Gallate
33%
Pseudomonas Aeruginosa (P. aeruginosa)
33%
Intravitreal Triamcinolone Acetonide Injection
33%
Asia
33%
Intravitreal Ranibizumab
33%
Penetrating Injury
33%
Stem Cell Secretome
33%
Matrix Metalloproteinases
33%
Cluster Analysis
33%
Pulmonary Tuberculosis
33%
Intravitreal
33%
Clinical Treatment
33%
Secretome
33%
Young Patients
33%
Therapeutic Potential
33%
Cutaneous mucormycosis
33%
Rhino-orbital
33%
Rare Presentation
33%
Fibrosis
30%
Low-income Countries
29%
High-income Countries
27%
Adipose-derived Mesenchymal Stem Cells (ADMSCs)
25%
Left Eye
25%
Inflammation
25%
ESBL-producing Enterobacteriaceae
25%
Low-middle Income Countries
23%
Pharmacology, Toxicology and Pharmaceutical Science
Triamcinolone Acetonide
100%
Bevacizumab
100%
Plasminogen Activator Inhibitor 1
46%
Vitreoretinopathy
42%
Tumor Necrosis Factor
40%
Interleukin 10
40%
Leporidae
38%
Wound Healing
34%
Antiinflammatory Activity
33%
Keratitis
33%
Pseudomonas aeruginosa
33%
Epigallocatechin Gallate
33%
Penetrating Trauma
33%
Matrix Metalloproteinase
33%
Transforming Growth Factor Beta
33%
Vasculotropin
31%
Inflammation
28%
Fibrosis
25%
Treatment Group
25%
Gelatinase A
22%
Tissue Inhibitor of Metalloproteinase
22%
Wound
16%
Anti-Inflammatory Drug
16%
Cancer Growth Factor
13%
Experimental Rabbit
10%
New Zealand Rabbit
10%
Rabbit Model
10%
Eye Injury
9%
Antioxidant
8%
Cornea Injury
8%
Cornea Perforation
8%
Camellia Sinensis
8%
Scar Formation
8%
Polyphenol
8%
Vitreous Hemorrhage
6%
Ranibizumab
6%
Aflibercept
6%
Conbercept
6%
Retina Detachment
6%
Interleukin 1
6%
Immunosuppressive Agent
6%
Intravitreal Administration
6%
Interleukin 2
6%
Interleukin 6
6%
Medicine and Dentistry
Retinoblastoma
100%
Bevacizumab
66%
Triamcinolone Acetonide
66%
Visual Acuity
46%
Enucleation
40%
Orbital Cellulitis
40%
Proliferative Vitreoretinopathy
33%
Lung Tuberculosis
33%
Scleromalacia
33%
Matrix Metalloproteinase
33%
Penetrating Trauma
33%
Mucormycosis
33%
Vasculotropin
26%
Fibrosis
25%
Extended Spectrum Beta Lactamase
25%
Metalloprotease Inhibitor
22%
Gelatinase A
22%
Diseases
20%
Low and Middle Income Countries
19%
Penicillinase
16%
Metastatic Carcinoma
16%
Systemic Autoimmune Disease
16%
Early Diagnosis
15%
Abscess
15%
Plasminogen Activator Inhibitor-1
13%
Cancer Growth Factor
13%
Wound
12%
Treatment Group
11%
Pus
8%
Hand Movement
8%
Acid Fast Bacterium
8%
Pneumonia
8%
Ectasia
8%
Eye Movement
8%
Pathognomonic
8%
HLA-B27
8%
Granulomatosis with Polyangiitis
8%
Posterior Vitreous Detachment
8%
Edema
8%
Photophobia
8%
Lupus Erythematosus
8%
Rheumatoid Arthritis
8%
Cosmetic
8%
Autoimmune Disease
8%
Chronic Inflammation
8%
Inflammatory Arthritis
8%
Comorbidity
8%
Dermis
8%
Cancer Staging
7%
Leukokoria
7%
